Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review

Por Yu, Da-Ping, Cheng, Xu, Liu, Zhi-Dong, Xu, Shao-Fa
Publicado no Oncol Lett (2017)

The clinicopathological significance of hMLH1 hypermethylation in non-small-cell lung cancer: a meta-analysis and literature review

Por Han, Yi, Shi, Kang, Zhou, Shi-Jie, Yu, Da-Ping, Liu, Zhi-Dong
Publicado no Onco Targets Ther (2016)

Clinicopathological significance and a potential drugtarget of RARβ in non-small-cell lung carcinoma: a meta-analysis and a systematic review

Por Song, Xiaoyun, Shi, Kang, Zhou, Shi-Jie, Yu, Da-Ping, Liu, Zhidong, Han, Yi
Publicado no Drug Des Devel Ther (2016)

Expression level of CRKL and AXL combined with exon 19 deletion in EGFR and ALK status confer differential prognosis of lung adenocarcinoma subtypes

Por Cai, Yi-Ran, Dong, Yu-Jie, Wu, Hong-Bo, Yu, Da-Ping, Zhou, Li-Juan, Su, Dan, Zhang, Li, Chen, Xue-Jing
Publicado no Oncol Lett (2016)

Differential expression of CRKL and AXL genes in lung adenocarcinoma subtypes according to the epidermal growth factor receptor and anaplastic lymphoma kinase gene status

Por YU, DA-PING, DONG, YU-JIE, ZHANG, HAI-QING, WANG, JING-HUI, QU, YANG, ZHOU, LI-JUAN, SU, DAN, ZHANG, LI-LI, ZHAO, DAN, CAI, YI-RAN
Publicado em 2014